A Phase 3 interventional study of Pitolisant in Idiopathic Hypersomnia and Excessive Daytime Sleepiness, sponsored by Harmony Biosciences Management, Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 15th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
Takeda · Sites in United States, Australia, China and 2 more countries
Ages 18–71
University of Pittsburgh · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Canada
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in United States, Canada, Italy and 1 more country
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 82 across 40 interventional studies indexed under Idiopathic Hypersomnia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Harmony Biosciences Management, Inc., one of the names counted as Harmony Biosciences Holdings, Inc.. Under that name alone:
Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Harmony Biosciences Holdings, Inc. has 3 studies filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Hypersomnia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT05837091Mayo ClinicLow Sodium Oxybate in Patients With Idiopathic Hypersomnia | 2027-01-29 |
Add all 5 to your calendar (.ics) → With an account.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.
This is a Phase 3 open-label study to evaluate the long-term safety and effectiveness of pitolisant in adult patients with IH. Patients who complete the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010 (i.e., completed the End-of-Treatment [EOT] Visit/Visit 5 in the HBS-101-CL-010 study) and who continue to meet eligibility criteria for study HBS-101-CL-011 are eligible for enrollment.
Enrolled patients will be dispensed open-label pitolisant and may be titrated up to a maximum dose of 35.6 mg, based on the Investigator's assessment of safety/tolerability and effectiveness, during a 3-week Titration Period (Day 1 to Day 21) in accordance with the schedule:
The Long-Term Dosing Period will begin on Day 22 and will continue until the patient discontinues from the study or the Sponsor elects to terminate the study (i.e., End-of-Study [EOS]).
An on-site study visit will occur approximately 180 days after Visit 2 on Day 202 (Visit 3). On-site study visits will occur approximately every 6 months and telephone contacts (TCs) approximately every one month in between until the patient withdraws from the study or the study is terminated by the Sponsor. The dose of pitolisant may be adjusted (higher or lower) in increments of 4.45 mg starting at 8.9 mg up to 35.6 mg during the Long-Term Dosing Period based on Investigator assessment of safety/tolerability and effectiveness.
All patients will receive safety follow-up TCs from the study site 15 days and 30 days after their final dose of pitolisant, to assess for adverse events (AEs) and concomitant medication use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening.
Drug: Pitolisant
Pitolisant 4.45 mg tablets Pitolisant 17.8 mg tablets
Number of Participants With Treatment Emergent Adverse Events (TEAE)
A TEAE was defined as any new adverse event or any worsening of a pre-existing condition that was reported after first dose of study drug and up to 30 days after the date of last dose of study drug.
Time frame: Up to approximately 3 years
Change From Baseline in Epworth Sleepiness Scale (ESS) Score
The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher scores represent more severe daytime sleepiness.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Score
The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score for IH (CGI-S [IH])
The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Patient Global Impression of Severity (PGI-S) Scale Score for Excessive Daytime Sleepiness (EDS) (PGI-S [EDS])
The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S \[EDS\]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Functional Outcomes of Sleep Questionnaire 10-item Version (FOSQ-10) Score
The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Item Bank v1.0-Short Form 8a (PROMIS-SRI SF 8a) Total T-Score
The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from 1 to 5. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40. T-score ranges from 30 to 80.1. Higher scores represent greater impairment. HealthMeasures reports that PROMIS-SRI SF 8a T-score mean is 50 with a standard deviation of 10 in the general population.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
Change From Baseline in Sleep Inertia Questionnaire (SIQ) Score
The Sleep Inertia Questionnaire (SIQ) score is the sum of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia.
Time frame: Baseline, Week 4 and Months 7, 13, 19, 25, 31
| Milestone | Pitolisant |
|---|---|
| Started | 119 |
| Received at least one dose of study treatment | 119 |
| Completed | 62 |
| Not completed | 57 |
| Withdrew: Withdrawal by subject | 19 |
| Withdrew: Lack of efficacy | 13 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Adverse event | 6 |
| Withdrew: Other : not specified | 6 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Non-compliance with study drug | 1 |
| Withdrew: Protocol violation | 1 |
A TEAE was defined as any new adverse event or any worsening of a pre-existing condition that was reported after first dose of study drug and up to 30 days after the date of last dose of study drug.
| Participants | Pitolisant |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAE) | 104 |
The Epworth Sleepiness Scale (ESS) is an 8-item, 4-point rating scale that asks participants to rate the likelihood of falling asleep over the past week. The rating scale ranges from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is calculated by summing the item level ratings. Total scores range from 0 to 24. Higher scores represent more severe daytime sleepiness.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | -3.7 ± 4.53 |
| Month 7 | -3.1 ± 5.13 |
| Month 13 | -3.4 ± 4.74 |
| Month 19 | -3.0 ± 5.83 |
| Month 25 | -4.0 ± 5.50 |
| Month 31 | -3.3 ± 3.44 |
The Idiopathic Hypersomnia Severity Scale (IHSS) is a self-administered questionnaire with a total of 14 items that assess long sleep duration and sleep inertia (5 items), daytime functioning (7 items), and napping (2 items). All items are scored from 0 to 3 or from 0 to 4. The total score is a sum of the item scores. The total score ranges from 0 to 50. A higher score indicates more severe and frequent symptoms.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | -6.4 ± 7.96 |
| Month 7 | -5.7 ± 8.17 |
| Month 13 | -6.4 ± 8.22 |
| Month 19 | -6.3 ± 9.14 |
| Month 25 | -6.0 ± 10.81 |
| Month 31 | -3.8 ± 3.82 |
The CGI-S (IH) is an investigator-rated assessment. It uses a single-item, 5-point Likert-type rating scale that ranges from: none (1); mild (2); moderate (3); severe (4); very severe (5). An assessment of less severe symptoms represents an improvement in the investigator's perception of the participant's overall clinical status related to idiopathic hypersomnia and is reflected by a decrease in score.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | -0.7 ± 1.07 |
| Month 7 | -0.7 ± 1.06 |
| Month 13 | -0.9 ± 0.99 |
| Month 19 | -0.8 ± 1.19 |
| Month 25 | -0.9 ± 1.11 |
| Month 31 | -0.7 ± 0.52 |
The Patient Global Impression of Severity for Excessive Daytime Sleepiness (PGI-S \[EDS\]) asks participants to rate their overall impression of the severity of their EDS over the past 7 days on a 5-point verbal rating scale ranging from "none" to "very severe". Scores are: 1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very Severe.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | -0.7 ± 1.17 |
| Month 7 | -0.7 ± 1.14 |
| Month 13 | -0.7 ± 1.07 |
| Month 19 | -0.6 ± 1.23 |
| Month 25 | -0.7 ± 1.30 |
| Month 31 | -0.5 ± 0.84 |
The Functional Outcomes of Sleep Questionnaire 10-Item Version (FOSQ-10) consists of 10 items assessing the impact of sleepiness on daily functioning across 5 domains: vigilance, general productivity, social outcomes, intimacy, and activity level. Each item is rated on a scale of 0 (activity not performed for other reasons), 1 (extreme difficulty), 2 (moderate difficulty), 3 (a little difficulty), and 4 (no difficulty). The FOSQ-10 total score is calculated by multiplying the mean of the subscale scores by five, with final scores ranging from 5-20. Higher scores correspond to less impairment/symptomatic severity.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | 1.685 ± 2.6414 |
| Month 7 | 1.801 ± 3.4167 |
| Month 13 | 2.054 ± 3.3404 |
| Month 19 | 2.054 ± 3.7440 |
| Month 25 | 2.433 ± 3.6093 |
| Month 31 | 2.813 ± 3.1331 |
The PROMIS-SRI SF 8a is a self-report measure that includes 8 questions designed to assess a participant's perceptions of their waking alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness over the past week. Responses are rated using a 5-point scale, with responses ranging from 1 to 5. Raw scores are converted to a T-score using the conversion table from the PROMIS-SRI Scoring Manual. Raw score ranges from 8 to 40. T-score ranges from 30 to 80.1. Higher scores represent greater impairment. HealthMeasures reports that PROMIS-SRI SF 8a T-score mean is 50 with a standard deviation of 10 in the general population.
| T-score | Pitolisant |
|---|---|
| Week 4 | -4.92 ± 7.124 |
| Month 7 | -3.75 ± 8.408 |
| Month 13 | -4.48 ± 7.778 |
| Month 19 | -4.90 ± 8.423 |
| Month 25 | -5.20 ± 9.170 |
| Month 31 | -3.48 ± 5.232 |
The Sleep Inertia Questionnaire (SIQ) score is the sum of 21 questions that assess sleep inertia. Each question is rated on a scale of 1 to 5, where: 1=not at all; 2=a little; 3=somewhat; 4=often; 5=all the time. Total scores range from 21 to 105. Higher scores represent greater sleep inertia.
| score on a scale | Pitolisant |
|---|---|
| Week 4 | -9.18 ± 15.74 |
| Month 7 | -8.4 ± 16.85 |
| Month 13 | -7.7 ± 16.92 |
| Month 19 | -8.0 ± 19.31 |
| Month 25 | -8.1 ± 22.77 |
| Month 31 | -8.8 ± 9.33 |
Collected over Up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitolisant | 0/119 (0%) | 6/119 (5%) | 84/119 (70.6%) |
| Event | Pitolisant |
|---|---|
| AppendicitisInfections and infestations | 1/119 |
| Breast cellulitisInfections and infestations | 1/119 |
| CellulitisInfections and infestations | 1/119 |
| Atrial fibrillationCardiac disorders | 1/119 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/119 |
| HypoaesthesiaNervous system disorders | 1/119 |
| Transient ischaemic attackNervous system disorders | 1/119 |
| DepressionPsychiatric disorders | 1/119 |
| Event | Pitolisant |
|---|---|
| COVID-19Infections and infestations | 27/119 |
| Upper respiratory tract infectionInfections and infestations | 20/119 |
| NasopharyngitisInfections and infestations | 16/119 |
| InsomniaPsychiatric disorders | 16/119 |
| HeadacheNervous system disorders | 14/119 |
| Urinary tract infectionInfections and infestations | 12/119 |
| SinusitisInfections and infestations | 9/119 |
| NauseaGastrointestinal disorders | 8/119 |
| Pharyngitis streptococcalInfections and infestations | 7/119 |
| BronchitisInfections and infestations | 6/119 |
| Age, Continuous(years) | Pitolisant |
|---|---|
| Mean | 40.1 ± 11.96 |
| Sex: Female, Male(Participants) | Pitolisant |
|---|---|
| Female | 95 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Pitolisant |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 111 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Pitolisant |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 106 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Oct 2025, 37 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitolisant
Harmony Biosciences Management, Inc. →